Project Updates » Archives » October 2016

Trouble in Chinese regulatory system

Author: Marya Lieberman

Derek Lowe's blog "In the Pipeline" reports on a story about massive problems in regulatory oversight of drug approval in China.  

A report in the Chinese newspaper Economic Information Daily says that the Chinese SFDA (State Food and Drug Administration) has been conducting a review of Chinese clinical trial practices, and after reviewing 1,622 trials has found that most of them are seriously flawed. And by “seriously flawed”, they mean “largely faked”. 

Read More